Towards a Physiological Prandial Insulin Profile: Enhancement of Subcutaneously Injected Prandial Insulin Using Local Warming Devices

Diabetes Therapy

Volumn 6, Issue 3, 2015, Pages 257-272

  El Laboudi, Ahmed H ^a,b   Oliver, Nick ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

Author keywords

Insulin absorption; Insulin therapy; InsuPad; InsuPatch; Postprandial glycaemia

Indexed keywords

INSULIN; INSULIN ASPART; INSULIN LISPRO; RECOMBINANT HYALURONIDASE;

AREA UNDER THE CURVE; BLOOD FLOW; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; PAIN INTENSITY; PRIORITY JOURNAL; QUESTIONNAIRE; REVIEW; SKIN TEMPERATURE; TRANSDERMAL PATCH;

EID: 84942324963     PISSN: 18696953     EISSN: 18696961     Source Type: Journal    
DOI: 10.1007/s13300-015-0125-z     Document Type: Review

References (48)

1. Arnolds S, et al. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes. Int J Clin Pract. 2010;64(10):1415–24.
2. Heinemann L, Muchmore DB. Ultrafast-acting insulins: state of the art. J Diabetes Sci Technol. 2012;6(4):728–42.
3. ter Braak EW, et al. Injection site effects on the pharmacokinetics and glucodynamics of insulin lispro and regular insulin. Diabetes Care. 1996;19(12):1437–40.
4. de la Pena A, et al. Pharmacokinetics and pharmacodynamics of high-dose human regular U-500 insulin versus human regular U-100 insulin in healthy obese subjects. Diabetes Care. 2011;34(12):2496–501.
5. Gagnon-Auger M, et al. Dose-dependent delay of the hypoglycemic effect of short-acting insulin analogs in obese subjects with type 2 diabetes: a pharmacokinetic and pharmacodynamic study. Diabetes Care. 2010;33(12):2502–7.
6. Bott S, et al. Impact of smoking on the metabolic action of subcutaneous regular insulin in type 2 diabetic patients. Horm Metab Res. 2005;37(7):445–9.
7. Dillon RS. Improved serum insulin profiles in diabetic individuals who massaged their insulin injection sites. Diabetes Care. 1983;6(4):399–401.
8. Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care. 2003;26(3):881–5.
9. Ceriello A, et al. Oscillating glucose is more deleterious to endothelial function and oxidative stress than mean glucose in normal and type 2 diabetic patients. Diabetes. 2008;57(5):1349–54.
10. Brownlee M, Hirsch IB. Glycemic variability: a hemoglobin A1c-independent risk factor for diabetic complications. JAMA. 2006;295(14):1707–8.
11. Home PD. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. Diabetes Obes Metab. 2012;14(9):780–8.
12. Heller SR, et al. Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. Diabet Med. 2004;21(7):769–75.
13. Mannucci E, Monami M, Marchionni N. Short-acting insulin analogues vs. regular human insulin in type 2 diabetes: a meta-analysis. Diabetes Obes Metab. 2009;11(1):53–9.
14. Plank J, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2005;165(12):1337–44.
15. Bruttomesso D, et al. Restoration of early rise in plasma insulin levels improves the glucose tolerance of type 2 diabetic patients. Diabetes. 1999;48(1):99–105.
16. Homko C, et al. Comparison of insulin aspart and lispro: pharmacokinetic and metabolic effects. Diabetes Care. 2003;26(7):2027–31.
17. Luijf YM, et al. Premeal injection of rapid-acting insulin reduces postprandial glycemic excursions in type 1 diabetes. Diabetes Care. 2010;33(10):2152–5.
18. Cobry E, et al. Timing of meal insulin boluses to achieve optimal postprandial glycemic control in patients with type 1 diabetes. Diabetes Technol Ther. 2010;12(3):173–7.
19. Scaramuzza AE, et al. Timing of bolus in children with type 1 diabetes using continuous subcutaneous insulin infusion (TiBoDi Study). Diabetes Technol Ther. 2010;12(2):149–52.
20. Santos Cavaiola T, Edelman S. Inhaled insulin: a breath of fresh air? A review of inhaled insulin. Clin Ther. 2014;36(8):1275–89.
21. Rini CJ, et al. Intradermal insulin infusion achieves faster insulin action than subcutaneous infusion for 3-day wear. Drug Deliv Transl Res. 2015;5(4):332–45.
22. Heinemann L, Jacques Y. Oral insulin and buccal insulin: a critical reappraisal. J Diabetes Sci Technol. 2009;3(3):568–84.
23. Sousa F, et al. How to overcome the limitations of current insulin administration with new non-invasive delivery systems. Ther Deliv. 2015;6(1):83–94.
24. Heinemann L, et al. U-100, pH-neutral formulation of VIAject((R)): faster onset of action than insulin lispro in patients with type 1 diabetes. Diabetes Obes Metab. 2012;14(3):222–7.
25. Heise T, et al. Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart. Diabetes Obes Metab. 2015;17:682–8.
26. Adocia. HinsBet: “Human insulin is better”. http://www.adocia.fr/WP/products/hinsbet-ultra-fast-acting-human-insulin/. Accessed 3 June 2015.
27. Andersen G, et al. The ultra-rapid biochaperone insulin lispro (BC LIS) shows a faster onset of action and stronger early metabolic effect than insulin lispro (LIS). In: Abstracts from ADA2014, 13–17 June 2014, San Francisco, CA, USA.
28. Morrow L, et al. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care. 2013;36(2):273–5.
29. Engwerda EE, et al. Improved pharmacokinetic and pharmacodynamic profile of rapid-acting insulin using needle-free jet injection technology. Diabetes Care. 2011;34(8):1804–8.
30. Engwerda EE, Tack CJ, de Galan BE. Needle-free jet injection of rapid-acting insulin improves early postprandial glucose control in patients with diabetes. Diabetes Care. 2013;36(11):3436–41.
31. Koivisto VA. Sauna-induced acceleration in insulin absorption from subcutaneous injection site. Br Med J. 1980;280(6229):1411–3.
32. Koivisto VA. Sauna-induced acceleration in insulin absorption. Br Med J. 1980;281(6240):621–2.
33. Sindelka G, et al. Effect of insulin concentration, subcutaneous fat thickness and skin temperature on subcutaneous insulin absorption in healthy subjects. Diabetologia. 1994;37(4):377–80.
34. Raz I, et al. Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. Clin Ther. 2009;31(5):980–7.
35. Freckmann G, et al. Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study. J Diabetes Sci Technol. 2012;6(2):320–7.
36. Landau Z, et al. Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. Diabetes Metab Res Rev. 2014;30(8):686–92.
37. Cengiz E, et al. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatr Diabetes. 2013;14(3):168–73.
38. Cengiz E, et al. Faster in and faster out: accelerating insulin absorption and action by insulin infusion site warming. Diabetes Technol Ther. 2014;16(1):20–5.
39. US NIH. ClinicalTrials.gov: Effect of the InsuPatch on automated closed-loop glucose control in type 1 diabetes (IPCL). https://clinicaltrials.gov/ct2/show/NCT01787318. Accessed 13 July 2015.
40. Pfützner A, et al. Effect of the InsuPad device on postprandial glucose excursion in type II diabetic subjects. Diabetes Technol Ther. 2013;15(suppl 1):A167.
41. Raz I, et al. Improved postprandial glucose control using the InsuPad device in insulin-treated type 2 diabetes: injection site warming to improve glycemic control. J Diabetes Sci Technol. 2015;9(3):639–43. doi:10.1177/1932296815578881.
42. Hermanns N, et al. Effect of local heating on postprandial blood glucose excursions using the InsuPad device: results of an outpatient crossover study. J Diabetes Sci Technol. 2014;8(6):1126–32.
43. Pfutzner A, et al. The Barmer study: impact of standardized warming of the injection site to enhance insulin absorption and reduce prandial insulin requirements and hypoglycemia in obese patients with diabetes mellitus. Curr Med Res Opin. 2014;30(5):753–60.
44. Pfutzner A, et al. Standardized modulation of the injection site allows for insulin dose reduction without deterioration of metabolic control. Curr Med Res Opin. 2014;30(10):2001–8.
45. Bitton G, et al. Effect of the Insupad device on post meal glucose and insulin levels with delayed insulin injections. Diabetes Technol Ther. 2014;16(P-216):A-83.
46. Pfutzner A, et al. Improved insulin absorption by means of standardized injection site modulation results in a safer and more efficient prandial insulin treatment. A review of the existing clinical data. J Diabetes Sci Technol. 2015;9(1):116–22.
47. Pfutzner A, et al. The impact of local warming at the insulin injection site by the use of the InsuPad device on treatment satisfaction and diabetes related distress. Diabetes Technol Ther. 2014; 16(P-226):A-88.
48. Pfutzner A, et al. Long-term use of InsuPad is associated with high treatment adherence, maintenance of excellent glycemic control and further reduction of prandial insulin requirements. Diabetes Technol Ther. 2015;17:A102.